Outcome of short-term antiepileptic treatment in patients with solitary cerebral cysticercus granuloma.
OBJECTIVE
The duration of antiepileptic drug (AED) therapy in cases of solitary cerebral cysticercus granuloma (SCCG) presents a major dilemma and the efficacy of short-term (6 months) vs long-term (2 years) AED therapy has been studied.


METHODS
Prospective randomized study of short-term vs long-term AED treatment with SCCG has been undertaken. A total of 206 subjects with new onset seizures with SCCG were randomized into two groups: group A (98 patients) were treated for 6 months and group B (108 patients) were treated for 2 years with AED therapy. The patients were evaluated periodically during and at least 18 months after the tapering of drugs.


RESULTS
Partial seizures with or without secondary generalization has been found to be the commonest manifestation occurring in 80.6% of patients with SCCG. In group A 66.3% and in group B 57.4% patients showed complete resolution of computerized tomographic lesion and rest had punctated residual calcification. Statistically, no significant difference in the recurrence of seizures was found in two groups with disappearance of lesion but the difference between calcified residua and complete resolution subset was significant. In patients having residual calcification, 42.2% in group A and 21.7% in group B had recurrence of seizures and the difference was statistically significant (Z = 1.97, P < 0.05).


CONCLUSIONS
The study revealed that SCCG with epilepsy is a benign self-limiting disease. A longer duration of therapy is not warranted in patients having total resolution of lesion. Calcified lesion was found to be the most common cause of recurrence of seizures. Higher recurrence rate was observed in short-term therapy in patients having calcified lesions and may require long-term AED treatment.
Verma
A
A
Department of Neurology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India. archanashiva@sify.com
Misra
S
S
D000293:Adolescent; D000328:Adult; D000818:Animals; D000927:Anticonvulsants / Q000627:therapeutic use*; D002114:Calcinosis; D003552:Cysticercus / Q000472:pathogenicity; D004334:Drug Administration Schedule; D005260:Female; D006099:Granuloma / Q000188:drug therapy* / Q000469:parasitology*; D006801:Humans; D008297:Male; D020019:Neurocysticercosis / Q000150:complications* / Q000188:drug therapy*; D011446:Prospective Studies; D012008:Recurrence; D012640:Seizures / Q000209:etiology*; D012720:Severity of Illness Index; D016896:Treatment Outcome
D000927:Anticonvulsants